Jefferies Financial Group Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $190.00

Becton, Dickinson and Company (NYSE:BDX) had its target price cut by stock analysts at Jefferies Financial Group from $220.00 to $190.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Jefferies Financial Group’s price target would indicate a potential upside of 5.33% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. JPMorgan Chase & Co. dropped their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday. Barclays assumed coverage on Becton, Dickinson and Company in a research report on Tuesday. They set an “overweight” rating and a $202.00 price target on the stock. Finally, Wells Fargo & Company cut their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $196.00.

Becton, Dickinson and Company Stock Up 5.1%

BDX stock opened at $180.39 on Tuesday. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. The firm has a 50 day simple moving average of $199.49 and a 200-day simple moving average of $192.35. The company has a market capitalization of $51.36 billion, a P/E ratio of 29.43, a PEG ratio of 1.90 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 2,463 shares of company stock worth $501,530. 0.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. RiverGlades Family Offices LLC purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth approximately $344,000. Transcend Capital Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 88.2% during the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares during the period. Belpointe Asset Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $650,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after purchasing an additional 34,437 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD closed its biosciences & diagnostics spin-off and merged that business with Waters, generating roughly $4 billion in proceeds and repositioning BD as a pure-play medical technology company — a strategic de‑risking that analysts and investors view favorably. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q1 FY2026: BD reported sales of ~$5.25B and EPS above consensus, and provided FY guidance — the beat + guidance underpin the bullish re-rating and help explain the intraday strength. BD (NYSE:BDX) Surprises With Q4 CY2025 Sales
• Positive Sentiment: High-profile endorsement: Jim Cramer publicly voiced support for the “new company” after the spin-off, which can boost retail interest and sentiment. Jim Cramer on Becton, Dickinson: “I kind of really like the new company”
• Positive Sentiment: BD launched cash tender offers to repurchase up to $1.6B of its outstanding debt, a move that can improve debt maturity profile and credit metrics. Investors often view targeted buybacks of debt as a constructive use of proceeds post‑spin. Becton Dickinson Launches $1.6 Billion Debt Tender Offers
• Neutral Sentiment: Analyst coverage and notes: Barclays initiated coverage with an Overweight and $202 PT (positive signal), while other firms adjusted targets — see items below; overall analyst activity is mixed and keeping volatility elevated. Barclays Overweight Note
• Neutral Sentiment: Earnings call transcript and post‑spin analysis provide more detail on margins, capital allocation and guidance assumptions for investors doing deeper due diligence. Q1 2026 earnings call transcript
• Negative Sentiment: Several high‑profile firms trimmed price targets or ratings: Wells Fargo cut its PT to $157 and moved to Equal Weight (notable downside from prior levels), and JPMorgan lowered its PT to $175 and maintained Neutral — these cuts add sell‑side caution. Analyst Target Changes (Wells Fargo / JPMorgan)
• Negative Sentiment: Other shops pared targets (RBC, Jefferies, Citi had updates); although many keep Buy/Overweight stances, the lower targets reflect uncertainty around near‑term margin recovery and the pace of capital deployment after the spin. Are Wall Street Analysts Bullish on Becton, Dickinson and Company Stock?

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.